Lawrence Kwong, PhD

Peer-Reviewed Articles

1. Zhu Y, Koleilat MKI, Roszik J, Kwong MK, Wang Z, Maru DM, Kopetz S, Kwong LN. A Gold Standard-Derived Modular Barcoding Approach to Cancer Transcriptomics. Cancers (Basel) 16(10), 2024. e-Pub 2024. PMID: 38791964.
2. Moffat GT, Hu ZI, Meric-Bernstam F, Kong EK, Pavlick D, Ross JS, Murugesan K, Kwong L, De Armas AD, Korkut A, Javle M, Knox JJ. KRAS Allelic Variants in Biliary Tract Cancers. JAMA Netw Open 7(5):e249840, 2024. e-Pub 2024. PMID: 38709532.
3. Makawita S, Lee S, Kong E, Kwong LN, Abouelfetouh Z, Danner De Armas A, Xiao L, Murugesan K, Danziger N, Pavlick D, Korkut A, Ross JS, Javle M. Comprehensive Immunogenomic Profiling of IDH1-/2-Altered Cholangiocarcinoma. JCO Precis Oncol 8:e2300544, 2024. e-Pub 2024. PMID: 38547421.
4. DiPeri TP, Zhao M, Evans KW, Varadarajan K, Moss T, Scott S, Kahle MP, Byrnes CC, Chen H, Lee SS, Halim AB, Hirai H, Wacheck V, Kwong LN, Rodon J, Javle M, Meric-Bernstam F. Convergent MAPK pathway alterations mediate acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma. J Hepatol 80(2):322-334, 2024. e-Pub 2024. PMID: 37972659.
5. Zhu Y, Zhang D, Shukla P, Jung YH, Malgulwar PB, Chagani S, Colic M, Benjamin S, Copland JA 3rd, Tan L, Lorenzi PL, Javle M, Huse JT, Roszik J, Hart T, Kwong LN. CRISPR screening identifies BET and mTOR inhibitor synergy in cholangiocarcinoma through serine glycine one carbon. JCI Insight 9(2), 2024. e-Pub 2024. PMID: 38060314.
6. Zhang DY, Zhu Y, Wu Q, Ma S, Ma Y, Shen ZC, Wang Z, Sun W, Zhou YC, Wang D, Zhou S, Liu Z, Kwong LN, Lu Z. USP1 promotes cholangiocarcinoma progression by deubiquitinating PARP1 to prevent its proteasomal degradation. Cell Death Dis 14(10):669, 2023. e-Pub 2023. PMID: 37821462.
7. Chagani S, De Macedo MP, Carapeto F, Wang F, Marzese DM, Wani K, Haydu LE, Peng W, Ong GT, Warren SE, Beechem JM, Hoon DSB, Mills GB, Tetzlaff MT, Lazar AJ, Kwong LN, Davies MA. Multiplatform Analysis of Intratumoral PTEN Heterogeneity in Melanoma. J Invest Dermatol 143(9):1779-1787.e1, 2023. e-Pub 2023. PMID: 36871660.
8. Romano G, Paradiso F, Li P, Shukla P, Barger LN, El Naggar O, Miller JP, Liang RJ, Helms TL, Lazar AJ, Wargo JA, Taraballi F, Costello JC, Kwong LN. Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma. Cancer Immunol Res 11(5):558-569, 2023. e-Pub 2023. PMID: 36820825.
9. Sorokin AV, Kanikarla Marie P, Bitner L, Syed M, Woods M, Manyam G, Kwong LN, Johnson B, Morris VK, Jones P, Menter DG, Lee MS, Kopetz S. Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6. Cancer Res 82(18):3335-3344, 2022. e-Pub 2022. PMID: 35913398.
10. Andrews MC, Oba J, Wu CJ, Zhu H, Karpinets T, Creasy CA, Forget MA, Yu X, Song X, Mao X, Robertson AG, Romano G, Li P, Burton EM, Lu Y, Sloane RS, Wani KM, Rai K, Lazar AJ, Haydu LE, Bustos MA, Shen J, Chen Y, Morgan MB, Wargo JA, Kwong LN, Haymaker CL, Grimm EA, Hwu P, Hoon DSB, Zhang J, Gershenwald JE, Davies MA, Futreal PA, Bernatchez C, Woodman SE. Multi-modal molecular programs regulate melanoma cell state. Nat Commun 13(1):4000, 2022. e-Pub 2022. PMID: 35810190.
11. Zhang K, Song P, Dai P, Zhang JX, Wu LR, Cheng LY, Pinto A, Kwong L, Cabrera K, Wen R, Zhang DY. Cost-Efficient Sequence-Based Nonextensible Oligonucleotide in Real-Time PCR and High-Throughput Sequencing. ACS Sens 7(4):1165-1174, 2022. e-Pub 2022. PMID: 35418222.
12. Carapeto F, Bozorgui B, Shroff RT, Chagani S, Solis Soto L, Foo WC, Wistuba I, Meric-Bernstam F, Shalaby A, Javle M, Korkut A, Kwong LN. The immunogenomic landscape of resected intrahepatic cholangiocarcinoma. Hepatology 75(2):297-308, 2022. e-Pub 2022. PMID: 34510503.
13. Lapin M, Huang HJ, Chagani S, Javle M, Shroff RT, Pant S, Gouda MA, Raina A, Madwani K, Holley VR, Call SG, Dustin DJ, Lanman RB, Meric-Bernstam F, Raymond VM, Kwong LN, Janku F. Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH-Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors. JCO Precis Oncol 6:e2100197, 2022. e-Pub 2022. PMID: 35171660.
14. Dai P, Wu LR, Chen SX, Wang MX, Cheng LY, Zhang JX, Hao P, Yao W, Zarka J, Issa GC, Kwong L, Zhang DY. Calibration-free NGS quantitation of mutations below 0.01% VAF. Nat Commun 12(1):6123, 2021. e-Pub 2021. PMID: 34675197.
15. Liu J, Rebecca VW, Kossenkov AV, Connelly T, Liu Q, Gutierrez A, Xiao M, Li L, Zhang G, Samarkina A, Zayasbazan D, Zhang J, Cheng C, Wei Z, Alicea GM, Fukunaga-Kalabis M, Krepler C, Aza-Blanc P, Yang CC, Delvadia B, Tong C, Huang Y, Delvadia M, Morias AS, Sproesser K, Brafford P, Wang JX, Beqiri M, Somasundaram R, Vultur A, Hristova DM, Wu LW, Lu Y, Mills GB, Xu W, Karakousis GC, Xu X, Schuchter LM, Mitchell TC, Amaravadi RK, Kwong LN, Frederick DT, Boland GM, Salvino JM, Speicher DW, Flaherty KT, Ronai ZA, Herlyn M. Neural crest-like stem cell transcriptome analysis identifies LPAR1 in melanoma progression and therapy resistance. Cancer Res 81(20):5230-5241, 2021. e-Pub 2021. PMID: 34462276.
16. Thirunavukarasu D, Cheng LY, Song P, Chen SX, Borad MJ, Kwong L, James P, Turner DJ, Zhang DY. Oncogene Concatenated Enriched Amplicon Nanopore Sequencing for rapid, accurate, and affordable somatic mutation detection. Genome Biol 22(1):227, 2021. e-Pub 2021. PMID: 34482832.
17. Wang B, Zhang W, Zhang G, Kwong L, Lu H, Tan J, Sadek N, Xiao M, Zhang J, Labrie M, Randell S, Beroard A, Sugarman E, Rebecca VW, Wei Z, Lu Y, Mills GB, Field J, Villanueva J, Xu X, Herlyn M, Guo W. Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma. Oncogene 40(37):5590-5599, 2021. e-Pub 2021. PMID: 34304249.
18. Kawaguchi Y, Kopetz S, Kwong L, Xiao L, Morris JS, Tran Cao HS, Tzeng CD, Chun YS, Lee JE, Vauthey JN. Genomic Sequencing and Insight into Clinical Heterogeneity and Prognostic Pathway Genes in Patients with Metastatic Colorectal Cancer. J Am Coll Surg 233(2):272-284.e13, 2021. e-Pub 2021. PMID: 34111531.
19. Cheng LY, Haydu LE, Song P, Nie J, Tetzlaff MT, Kwong LN, Gershenwald JE, Davies MA, Zhang DY. High sensitivity sanger sequencing detection of BRAF mutations in metastatic melanoma FFPE tissue specimens. Sci Rep 11(1):9043, 2021. e-Pub 2021. PMID: 33907234.
20. Abdel-Wahab R, Yap TA, Madison R, Pant S, Cooke M, Wang K, Zhao H, Bekaii-Saab T, Karatas E, Kwong LN, Meric-Bernstam F, Borad M, Javle M. Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer. Sci Rep 10(1):22087, 2020. e-Pub 2020. PMID: 33328484.
21. Reicher A, Harris AL, Prinz F, Kiesslich T, Wei M, Öllinger R, Rad R, Pichler M, Kwong LN. Generation of An Endogenous FGFR2-BICC1 Gene Fusion/58 Megabase Inversion Using Single-Plasmid CRISPR/Cas9 Editing in Biliary Cells. Int J Mol Sci 21(7), 2020. e-Pub 2020. PMID: 32252259.
22. Cao J, Hu J, Liu S, Meric-Bernstam F, Abdel-Wahab R, Xu J, Li Q, Yan M, Feng Y, Lin J, Zhao S, Wang J, Kwong LN, Hu J, Carapeto F, Borad MJ, Wang K, Javle M, Zhao H. Intrahepatic Cholangiocarcinoma: Genomic Heterogeneity Between Eastern and Western Patients. JCO Precis Oncol 4, 2020. e-Pub 2020. PMID: 32923885.
23. Ziemys A, Kim M, Menzies AM, Wilmott JS, Long GV, Scolyer RA, Kwong L, Holder A, Boland G. Integration of Digital Pathologic and Transcriptomic Analyses Connects Tumor-Infiltrating Lymphocyte Spatial Density With Clinical Response to BRAF Inhibitors. Front Oncol 10:757, 2020. e-Pub 2020. PMID: 32528881.
24. Aloia A, Müllhaupt D, Chabbert CD, Eberhart T, Flückiger-Mangual S, Vukolic A, Eichhoff O, Irmisch A, Alexander LT, Scibona E, Frederick DT, Miao B, Tian T, Cheng C, Kwong LN, Wei Z, Sullivan RJ, Boland GM, Herlyn M, Flaherty KT, Zamboni N, Dummer R, Zhang G, Levesque MP, Krek W, Kovacs WJ. A Fatty Acid Oxidation-dependent Metabolic Shift Regulates the Adaptation of BRAF-mutated Melanoma to MAPK Inhibitors. Clin Cancer Res 25(22):6852-6867, 2019. e-Pub 2019. PMID: 31375515.
25. Santos-Pinheiro F, Park M, Liu D, Kwong LN, Cruz S, Levine NB, O'Brien BJ, Chen M. Seizure burden pre- and postresection of low-grade gliomas as a predictor of tumor progression in low-grade gliomas. Neurooncol Pract 6(3):209-217, 2019. e-Pub 2019. PMID: 31386048.
26. Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, Ju Z, Hansel D, de Velasco G, Pennathur A, Andersen JB, O'Rourke CJ, Ohshiro K, Jogunoori W, Nguyen BN, Li S, Osmanbeyoglu HU, Ajani JA, Mani SA, Houseman A, Wiznerowicz M, Chen J, Gu S, Ma W, Zhang J, Tong P, Cherniack AD, Deng C, Resar L, Weinstein JN, Mishra L, Akbani R. A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-beta Superfamily. Cell Syst 7(4):422-437.e7, 2018. e-Pub 2018. PMID: 30268436.
27. Zhang G, Wu LW, Mender I, Barzily-Rokni M, Hammond MR, Ope O, Cheng C, Vasilopoulos T, Randell S, Sadek N, Beroard A, Xiao M, Tian T, Tan J, Saeed U, Sugarman E, Krepler C, Brafford P, Sproesser K, Murugan S, Somasundaram R, Garman B, Wubbenhorst B, Woo J, Yin X, Liu Q, Frederick DT, Miao B, Xu W, Karakousis GC, Xu X, Schuchter LM, Mitchell TC, Kwong LN, Amaravadi RK, Lu Y, Boland GM, Wei Z, Nathanson K, Herbig U, Mills GB, Flaherty KT, Herlyn M, Shay JW. Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma. Clin Cancer Res 24(19):4771-4784, 2018. e-Pub 2018. PMID: 29563139.
28. Santos-Pinheiro F, Park M, Liu D, O’Brien BJ, Kwong LN, Levine NB, Chen M. Seizure Burden Pre- and Post-Resection of Low Grade Gliomas as a Predictor of Tumor Progression in Low-Grade Gliomas. Neuro-Oncology Practice, 2018. e-Pub 2018.
29. Kwong LN, De Macedo MP, Haydu L, Joon A, Calderone TL, Wu CJ, Kwong MK, Hess K, Davies MA, Lazar AJ, Gershenwald JE. Biological Validation of RNA Sequencing Data from Formalin-Fixed Paraffin-Embedded Primary Melanomas. JCO Precision Oncology, 2018. e-Pub 2018.
30. Teh JLF, Cheng PF, Purwin TJ, Nikbakht N, Patel P, Chervoneva I, Ertel A, Fortina PM, Kleiber I, HooKim K, Davies MA, Kwong LN, Levesque MP, Dummer R, Aplin AE. In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2-CDK4/6 Targeting and mTOR-S6 Resistance Mechanisms. Cancer Discov 8(5):568-581, 2018. e-Pub 2018. PMID: 29496664.
31. Romano G, Chen PL, Song P, McQuade JL, Liang RJ, Liu M, Roh W, Duose DY, Carapeto FCL, Li J, Teh JLF, Aplin AE, Chen M, Zhang J, Lazar AJ, Davies MA, Futreal PA, Amaria RN, Zhang DY, Wargo JA, Kwong LN. A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling. Cancer Discov 8(5):556-567, 2018. e-Pub 2018. PMID: 29496665.
32. Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Bailey MH, Liang WW, Foltz SM, Shmulevich I, Ding L, Heins Z, Ochoa A, Gross B, Gao J, Zhang H, Kundra R, Kandoth C, Bahceci I, Dervishi L, Dogrusoz U, Zhou W, Shen H, Laird PW, Way GP, Greene CS, Liang H, Xiao Y, Wang C, Iavarone A, Berger AH, Bivona TG, Lazar AJ, Hammer GD, Giordano T, Kwong LN, McArthur G, Huang C, Tward AD, Frederick MJ, McCormick F, Meyerson M, Research Network CGA, Van Allen EM, Cherniack AD, Ciriello G, Sander C, Schultz N. Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell 173(2):321-337.e10, 2018. e-Pub 2018. PMID: 29625050.
33. Yun C, Dashwood WM, Kwong LN, Gao S, Yin T, Ling Q, Singh R, Dashwood RH, Hu M. Accurate quantification of PGE2 in the polyposis in rat colon (Pirc) model by surrogate analyte-based UPLC-MS/MS. J Pharm Biomed Anal 148:42-50, 2018. e-Pub 2018. PMID: 28957718.
34. Kwong LN, De Macedo MP, Haydu L, Joon AY, Tetzlaff MT, Calderone TL, Wu CJ, Kwong MK, Roszik J, Hess KR, Davies MA, Lazar AJ, Gershenwald JE. Biological Validation of RNA Sequencing Data from Formalin-Fixed Paraffin-Embedded Primary Melanomas. JCO Precis Oncol 2018, 2018. e-Pub 2018. PMID: 31058252.
35. Johnson MB, Pang B, Gardner DJ, Niknam-Benia S, Soundarajan V, Bramos A, Perrault DP, Banks K, Lee GK, Baker RY, Kim GH, Lee S, Chai Y, Chen M, Li W, Kwong L, Hong YK, Wong AK. Topical Fibronectin Improves Wound Healing of Irradiated Skin. Sci Rep 7(1):3876, 2017. e-Pub 2017. PMID: 28634413.
36. Kwong LN, Zou L, Chagani S, Pedamallu CS, Liu M, Jiang S, Protopopov A, Zhang J, Getz G, Chin L. Modeling Genomic Instability and Selection Pressure in a Mouse Model of Melanoma. Cell Rep 19(7):1304-1312, 2017. e-Pub 2017. PMID: 28514651.
37. Vitiello M, Tuccoli A, D'Aurizio R, Sarti S, Giannecchini L, Lubrano S, Marranci A, Evangelista M, Peppicelli S, Ippolito C, Barravecchia I, Guzzolino E, Montagnani V, Gowen M, Mercoledi E, Mercatanti A, Comelli L, Gurrieri S, Wu LW, Ope O, Flaherty K, Boland GM, Hammond MR, Kwong L, Chiariello M, Stecca B, Zhang G, Salvetti A, Angeloni D, Pitto L, Calorini L, Chiorino G, Pellegrini M, Herlyn M, Osman I, Poliseno L. Context-dependent miR-204 and miR-211 affect the biological properties of amelanotic and melanotic melanoma cells. Oncotarget 8(15):25395-25417, 2017. e-Pub 2017. PMID: 28445987.
38. Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, Yang JD, Reznik E, Sadeghi S, Pedamallu CS, Ojesina AI, Hess JM, Auman JT, Rhie SK, Bowlby R, Borad MJ, Atlas Network CG, Zhu AX, Stuart JM, Sander C, Akbani R, Cherniack AD, Deshpande V, Mounajjed T, Foo WC, Torbenson MS, Kleiner DE, Laird PW, Wheeler DA, McRee AJ, Bathe OF, Andersen JB, Bardeesy N, Roberts LR, Kwong LN. Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles. Cell Rep 18(11):2780-2794, 2017. e-Pub 2017. PMID: 28297679.
39. Genovese G, Carugo A, Tepper J, Robinson FS, Li L, Svelto M, Nezi L, Corti D, Minelli R, Pettazzoni P, Gutschner T, Wu CC, Seth S, Akdemir KC, Leo E, Amin S, Molin MD, Ying H, Kwong LN, Colla S, Takahashi K, Ghosh P, Giuliani V, Muller F, Dey P, Jiang S, Garvey J, Liu CG, Zhang J, Heffernan TP, Toniatti C, Fleming JB, Goggins MG, Wood LD, Sgambato A, Agaimy A, Maitra A, Roberts CW, Wang H, Viale A, DePinho RA, Draetta GF, Chin L. Synthetic vulnerabilities of mesenchymal subpopulations in pancreatic cancer. Nature 542(7641):362-366, 2017. e-Pub 2017. PMID: 28178232.
40. Boutin AT, Liao WT, Wang M, Hwang SS, Karpinets TV, Cheung H, Chu GC, Jiang S, Hu J, Chang K, Vilar E, Song X, Zhang J, Kopetz S, Futreal A, Wang YA, Kwong LN, DePinho RA. Oncogenic Kras drives invasion and maintains metastases in colorectal cancer. Genes Dev 31(4):370-382, 2017. e-Pub 2017. PMID: 28289141.
41. Chen J, Shukla V, Farci P, Andricovich J, Jogunoori W, Kwong LN, Katz LH, Shetty K, Rashid A, Su X, White J, Li L, Wang AY, Blechacz B, Raju GS, Davila M, Nguyen BN, Stroehlein JR, Chen J, Kim SS, Levin H, Machida K, Tsukamoto H, Michaely P, Tzatsos A, Mishra B, Amdur R, Mishra L. Loss of the transforming growth factor-β effector β2-Spectrin promotes genomic instability. Hepatology 65(2):678-693, 2017. e-Pub 2017. PMID: 28114741.
42. Rose AA, Annis MG, Frederick DT, Biondini M, Dong Z, Kwong L, Chin L, Keler T, Hawthorne T, Watson IR, Flaherty KT, Siegel PM. MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB. Clin Cancer Res 22(24):6088-6098, 2016. e-Pub 2016. PMID: 27515299.
43. Chen PL, Roh W, Reuben A, Cooper ZA, Spencer CN, Prieto PA, Miller JP, Bassett RL, Gopalakrishnan V, Wani K, De Macedo MP, Austin-Breneman JL, Jiang H, Chang Q, Reddy SM, Chen WS, Tetzlaff MT, Broaddus RJ, Davies MA, Gershenwald JE, Haydu L, Lazar AJ, Patel SP, Hwu P, Hwu WJ, Diab A, Glitza IC, Woodman SE, Vence LM, Wistuba II, Amaria RN, Kwong LN, Prieto V, Davis RE, Ma W, Overwijk WW, Sharpe AH, Hu J, Futreal PA, Blando J, Sharma P, Allison JP, Chin L, Wargo JA. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. Cancer Discov 6(8):827-37, 2016. e-Pub 2016. PMID: 27301722.
44. Lee MS, Helms TL, Feng N, Gay J, Chang QE, Tian F, Wu JY, Toniatti C, Heffernan TP, Powis G, Kwong LN, Kopetz S. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models. Oncotarget 7(26):39595-39608, 2016. e-Pub 2016. PMID: 27167191.
45. Lu H, Liu S, Zhang G, Kwong LN, Zhu Y, Miller JP, Hu Y, Zhong W, Zeng J, Wu L, Krepler C, Sproesser K, Xiao M, Xu W, Karakousis GC, Schuchter LM, Field J, Zhang PJ, Herlyn M, Xu X, Guo W. Oncogenic BRAF-Mediated Melanoma Cell Invasion. Cell Rep 15(9):2012-24, 2016. e-Pub 2016. PMID: 27210749.
46. Peng W, Chen JQ, Liu C, Malu S, Creasy C, Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, Williams LJ, Deng W, Chen G, Mbofung R, Lazar AJ, Torres-Cabala CA, Cooper ZA, Chen PL, Tieu TN, Spranger S, Yu X, Bernatchez C, Forget MA, Haymaker C, Amaria R, McQuade JL, Glitza IC, Cascone T, Li HS, Kwong LN, Heffernan TP, Hu J, Bassett RL, Bosenberg MW, Woodman SE, Overwijk WW, Lizée G, Roszik J, Gajewski TF, Wargo JA, Gershenwald JE, Radvanyi L, Davies MA, Hwu P. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov 6(2):202-16, 2016. e-Pub 2016. PMID: 26645196.
47. Roszik J, Wu CJ, Siroy AE, Lazar AJ, Davies MA, Woodman SE, Kwong LN. Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression. Sci Rep 6:19649, 2016. e-Pub 2016. PMID: 26787600.
48. Rai K, Akdemir KC, Kwong LN, Fiziev P, Wu CJ, Keung EZ, Sharma S, Samant NS, Williams M, Axelrad JB, Shah A, Yang D, Grimm EA, Barton MC, Milton DR, Heffernan TP, Horner JW, Ekmekcioglu S, Lazar AJ, Ernst J, Chin L. Dual Roles of RNF2 in Melanoma Progression. Cancer Discov 5(12):1314-27, 2015. e-Pub 2015. PMID: 26450788.
49. Atlas Network CG. Genomic Classification of Cutaneous Melanoma. Cell 161(7):1681-96, 2015. e-Pub 2015. PMID: 26091043.
50. Kwong LN, Boland GM, Frederick DT, Helms TL, Akid AT, Miller JP, Jiang S, Cooper ZA, Song X, Seth S, Kamara J, Protopopov A, Mills GB, Flaherty KT, Wargo JA, Chin L. Co-clinical assessment identifies patterns of BRAF inhibitor resistance in melanoma. J Clin Invest 125(4):1459-70, 2015. e-Pub 2015. PMID: 25705882.
51. Kwong LN, Chin L. Chromosome 10, frequently lost in human melanoma, encodes multiple tumor-suppressive functions. Cancer Res 74(6):1814-21, 2014. e-Pub 2014. PMID: 24453001.
52. Martz CA, Ottina KA, Singleton KR, Jasper JS, Wardell SE, Peraza-Penton A, Anderson GR, Winter PS, Wang T, Alley HM, Kwong LN, Cooper ZA, Tetzlaff M, Chen PL, Rathmell JC, Flaherty KT, Wargo JA, McDonnell DP, Sabatini DM, Wood KC. Systematic identification of signaling pathways with potential to confer anticancer drug resistance. Sci Signal 7(357):ra121, 2014. e-Pub 2014. PMID: 25538079.
53. Frederick DT, Salas Fragomeni RA, Schalck A, Ferreiro-Neira I, Hoff T, Cooper ZA, Haq R, Panka DJ, Kwong LN, Davies MA, Cusack JC, Flaherty KT, Fisher DE, Mier JW, Wargo JA, Sullivan RJ. Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics. PLoS One 9(7):e101286, 2014. e-Pub 2014. PMID: 24983357.
54. Kwong LN, Costello JC, Liu H, Jiang S, Helms TL, Langsdorf AE, Jakubosky D, Genovese G, Muller FL, Jeong JH, Bender RP, Chu GC, Flaherty KT, Wargo JA, Collins JJ, Chin L. Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med 18(10):1503-10, 2012. e-Pub 2012. PMID: 22983396.
55. Muller FL, Colla S, Aquilanti E, Manzo VE, Genovese G, Lee J, Eisenson D, Narurkar R, Deng P, Nezi L, Lee MA, Hu B, Hu J, Sahin E, Ong D, Fletcher-Sananikone E, Ho D, Kwong L, Brennan C, Wang YA, Chin L, DePinho RA. Passenger deletions generate therapeutic vulnerabilities in cancer. Nature 488(7411):337-42, 2012. e-Pub 2012. PMID: 22895339.
56. Genovese G, Ergun A, Shukla SA, Campos B, Hanna J, Ghosh P, Quayle SN, Rai K, Colla S, Ying H, Wu CJ, Sarkar S, Xiao Y, Zhang J, Zhang H, Kwong L, Dunn K, Wiedemeyer WR, Brennan C, Zheng H, Rimm DL, Collins JJ, Chin L. microRNA regulatory network inference identifies miR-34a as a novel regulator of TGF-β signaling in glioblastoma. Cancer Discov 2(8):736-49, 2012. e-Pub 2012. PMID: 22750848.
57. Chen M, Lee G, Kwong LN, Lamont S, Chaves C. Cerebral white matter lesions in patients with Crohn's disease. J Neuroimaging 22(1):38-41, 2012. e-Pub 2012. PMID: 21091817.
58. Kabbarah O, Nogueira C, Feng B, Nazarian RM, Bosenberg M, Wu M, Scott KL, Kwong LN, Xiao Y, Cordon-Cardo C, Granter SR, Ramaswamy S, Golub T, Duncan LM, Wagner SN, Brennan C, Chin L. Integrative genome comparison of primary and metastatic melanomas. PLoS One 5(5):e10770, 2010. e-Pub 2010. PMID: 20520718.
59. Kwong LN, Weiss KR, Haigis KM, Dove WF. Atm is a negative regulator of intestinal neoplasia. Oncogene 27(7):1013-8, 2008. e-Pub 2008. PMID: 17700532.
60. Kwong LN, Shedlovsky A, Biehl BS, Clipson L, Pasch CA, Dove WF. Identification of Mom7, a novel modifier of Apc(Min/+) on mouse chromosome 18. Genetics 176(2):1237-44, 2007. e-Pub 2007. PMID: 17435219.
61. Amos-Landgraf JM, Kwong LN, Kendziorski CM, Reichelderfer M, Torrealba J, Weichert J, Haag JD, Chen KS, Waller JL, Gould MN, Dove WF. A target-selected Apc-mutant rat kindred enhances the modeling of familial human colon cancer. Proc Natl Acad Sci U S A 104(10):4036-41, 2007. e-Pub 2007. PMID: 17360473.

Invited Articles

1. Song P, Wu LR, Yan YH, Zhang JX, Chu T, Kwong LN, Patel AA, Zhang DY. Limitations and opportunities of technologies for the analysis of cell-free DNA in cancer diagnostics. Nat Biomed Eng 6(3):232-245, 2022. e-Pub 2022. PMID: 35102279.
2. Zhu Y, Kwong LN. Insights Into the Origin of Intrahepatic Cholangiocarcinoma From Mouse Models. Hepatology 72(1):305-314, 2020. e-Pub 2020. PMID: 32096245.
3. Reicher A, Foßelteder J, Kwong LN, Pichler M. Crosstalk between the Notch signaling pathway and long non-coding RNAs. Cancer Lett 420:91-96, 2018. e-Pub 2018. PMID: 29409809.
4. Romano G, Kwong LN. miRNAs, Melanoma and Microenvironment: An Intricate Network. Int J Mol Sci 18(11), 2017. e-Pub 2017. PMID: 29112174.
5. Abou-Alfa GK, Andersen JB, Chapman W, Choti M, Forbes SJ, Gores GJ, Hong TS, Harding JJ, Vander Heiden MG, Javle M, Kelley RK, Kwong LN, Lowery M, Merrell A, Miyabe K, Rhim A, Saha S, Sia D, Tanasanvimon S, Venook A, Valle JW, Walesky C, Whetstine J, Willenbring H, Zhu AX, Mayer D, Stanger BZ. Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference. J Gastrointest Oncol 7(6):819-827, 2016. e-Pub 2016. PMID: 28078106.
6. Jain A, Kwong LN, Javle M. Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice. Curr Treat Options Oncol 17(11):58, 2016. e-Pub 2016. PMID: 27658789.
7. Kwong LN, Davies MA. Targeted therapy for melanoma: rational combinatorial approaches. Oncogene 33(1):1-9, 2014. e-Pub 2014. PMID: 23416974.
8. Kwong LN, Heffernan TP, Chin L. A systems biology approach to personalizing therapeutic combinations. Cancer Discov 3(12):1339-44, 2013. e-Pub 2013. PMID: 24327696.
9. Kwong LN, Davies MA. Navigating the therapeutic complexity of PI3K pathway inhibition in melanoma. Clin Cancer Res 19(19):5310-9, 2013. e-Pub 2013. PMID: 24089444.
10. Heyer J, Kwong LN, Lowe SW, Chin L. Non-germline genetically engineered mouse models for translational cancer research. Nat Rev Cancer 10(7):470-80, 2010. e-Pub 2010. PMID: 20574449.
11. Kwong L, Chin L, Wagner SN. Growth factors and oncogenes as targets in melanoma: lost in translation?. Adv Dermatol 23:99-129, 2007. e-Pub 2007. PMID: 18159898.

Review Articles

1. Romano G, Chagani S, Kwong LN. The path to metastatic mouse models of colorectal cancer. Oncogene 37(19):2481-2489, 2018. e-Pub 2018. PMID: 29463860.
2. Romano G, Kwong LN. Diagnostic and therapeutic applications of miRNA-based strategies to cancer immunotherapy. Cancer Metastasis Rev 37(1):45-53, 2018. e-Pub 2018. PMID: 29270700.

Editorials

1. Zhu Y, Kwong LN. IDH1 Inhibition Reawakens the Immune Response against Cholangiocarcinoma. Cancer Discov 12(3):604-605, 2022. PMID: 35257150.
2. Chagani S, Kwong LN. Cholangiocarcinoma risk factors open the floodgates for gut microbes and immunosuppressive myeloid cells. Cancer Discov 11(5):1014-1015, 2021. PMID: 33947718.
3. Koleilat MK, Kwong LN. Same name, different game: EGFR drives intrinsic KRAS-G12C inhibitor resistance in colorectal cancer. Cancer Discov 10(8):1094-1096, 2020. PMID: 32747369.
4. Romano G, Kwong LN. BRAF Dimerization: An Underlying Resistance Mechanism in Low-Grade Pediatric Gliomas. Cancer Discov 8(9):1064-1065, 2018. PMID: 30181170.
5. Kwong LN, Chin L. The brothers RAF. Cell 140(2):180-2, 2010. PMID: 20141832.
6. Kwong LN, Chin L. The metastasis problem gets stickier. Cancer Cell 15(1):1-2, 2009. PMID: 19111873.

Book Chapters

1. Kwong LN, Dove WF. APC and its modifiers in colon cancer. In: Adv Exp Med Biol, 85-106, 2009.
2. Fisher DE, Kwong LN, Chin L. Molecular Biology of Cutaneous Melanoma. In: Cancer: Principles and Practice of Oncology. 8th ed, 2008.

Patents

1. A Germline Truncating Mutation in the Rat Adenomatous Polyposis Coli Gene Within the Human Mutation Hotspot Region. Patent Number: 20070143867.